Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Brexpiprazole - Lundbeck/Otsuka

Next Previous
X
Search
Drug Profile

Brexpiprazole - Lundbeck/Otsuka

Alternative Names: Lu-AF41156; OPC-34712; OPC-34712 FUM; OPDC-34712; Rexulti; REXULTIOD; Rxulti

Latest Information Update: 23 Aug 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Otsuka Pharmaceutical Development & Commercialization
  • Developer Lundbeck A/S; Otsuka Beijing Research Institute; Otsuka Pharmaceutical Development & Commercialization; University of Chicago
  • Class Antidepressants; Antipsychotics; Behavioural disorder therapies; Piperazines; Quinolines; Sleep disorder therapies; Small molecules; Thiophenes
  • Mechanism of Action Dopamine D2 receptor partial agonists; Serotonin 1A receptor partial agonists; Serotonin 5-HT2A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Agitation; Major depressive disorder; Schizophrenia
  • Preregistration Post-traumatic stress disorders
  • Phase III Bipolar disorders; Pervasive child development disorders; Sleep disorders
  • Discontinued Attention-deficit hyperactivity disorder; Borderline personality disorders

Most Recent Events

  • 30 Jun 2024 Registered for Schizophrenia in China (PO) before June 2024 (Otsuka Pharmaceutical pipeline, August 2024)
  • 25 Jun 2024 Preregistration for Post-traumatic stress disorders (Combination therapy) in USA (PO) prior to June 2024
  • 25 Jun 2024 FDA assigns PDUFA action date of 08/02/2025 for brexpiprazole for Post-traumatic stress disorder

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top